4.5 Article

Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamina1 in MDA-MB-231 and MCF-7 breast cancer cells

Journal

MOLECULAR AND CELLULAR ENDOCRINOLOGY
Volume 194, Issue 1-2, Pages 123-133

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/S0303-7207(02)00154-5

Keywords

peroxisome proliferator-activated receptor; estrogen receptor alpha; estrogen receptor beta; MCF-7 cells; MDA-MB-231 cells

Funding

  1. NCRR NIH HHS [P20 RR 15592] Funding Source: Medline
  2. NIDA NIH HHS [5K12 DA 14040-02] Funding Source: Medline

Ask authors/readers for more resources

We have previously demonstrated that peroxisome proliferator-activated receptor gamma (PPARgamma) is expressed and transcriptionally responsive to both synthetic and natural ligands in a variety of human breast cancer cells. We also observed significant differences in basal and ligand-mediated transactivation of PPARgamma in cells with variable expression of the estrogen receptor. While previous reports indicate that PPARgamma can mediate the expression of estrogen target genes, no data have suggested that estrogen receptor (ER) expression can alter the transcriptional regulation of PPARgamma target gene expression. Here we have demonstrated that the expression of either ERalpha or beta, but not the androgen or aryl hydrocarbon receptors, lowers both basal and stimulated PPARgamma-mediated reporter activity. Interestingly, the presence of an ER antagonist does not inhibit this response while estradiol treatment further inhibits the ligand-stimulated transactivation of PPARgamma in cells expressing ERalpha but not ERbeta. Cells transfected with ERalpha deletion mutants demonstrate that the DNA binding domain of the ER is required to repress PPAR transactivation in these cells. Finally, using RNase protection assays we show that the inhibition of PPAR function is not due to a decrease in the expression of PPARgamma. These data suggest that signal cross talk exists bidirectionally between PPARgamma and ER in breast cancer cells. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available